Beamr video compression achieves up to 50% improvement for AVs
Stephen P. Ewald, General Counsel & Corp. Secy. at Medpace Holdings, Inc. (NASDAQ:MEDP), sold 3,000 shares of common stock on July 28, 2025. The shares were sold at a price of $450, for a total transaction value of $1,350,000.
Following the transaction, Ewald directly owns 10,343 shares of Medpace Holdings, Inc.
The sale was executed according to a limit order placed by Ewald during an open window period.
Ewald has agreed to voluntarily disgorge to Medpace Holdings, Inc. all statutory "profits" pursuant to Section 16(b) of the Securities Exchange Act of 1934, as amended, that resulted from the reported transactions and the purchase of two shares within the past six months.
In other recent news, Medpace reported impressive financial results for the second quarter of 2025, with earnings per share reaching $3.10, surpassing the anticipated $2.98. The company also exceeded revenue forecasts, reporting $603.3 million compared to the expected $538.81 million. Despite these strong results, UBS downgraded Medpace from Neutral to Sell, although it slightly increased its price target to $305.00. Similarly, TD Cowen downgraded Medpace from Hold to Sell, even as it raised its price target to $366.00. UBS maintained a Neutral rating with a $300.00 price target, citing a mixed outlook despite Medpace’s better-than-expected Q2 bookings and sales. Analysts from both firms noted that recent stock surges might be influenced by factors other than fundamental business improvements. These developments reflect a complex investor sentiment surrounding Medpace’s future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.